Using both the PARP1 inhibitor, Olaparib, and OXA in combination effectively inhibited the viability, size, cell count, and proliferation of the organoids derived from the OXA resistance gastric cancers (rGC1 and rGC2) (P < 0.05) (Figures 4A–C). This evidence concerns the gene PARP1 and gastric cancer.